Table 2.

Correlations between SIK1 expression and clinical characteristics of patients with CRC

Groups	Case	%	SIK1 expression in cancer tissue
Low expression	%	High expression	%	x2	P-value
Gender
Male	57	56.44	40	54.79	17	60.71	0.288	0.591
Female	44	43.56	33	45.21	11	39.29
Age (y)
≤65	62	61.39	43	58.90	19	67.86	0.684	0.408
>65	39	38.61	30	41.10	9	32.14
Tumor location
Colon	56	55.45	35	47.95	21	75.00	7.119	0.008
Rectum	45	44.55	38	52.05	6	21.43
Differentiation
Well and Moderate	84	83.17	65	89.04	19	67.86	6.488	0.011
Worse	17	16.83	8	10.96	9	32.14
Initial CEA (ng/mL)
<20	70	69.31	52	71.23	18	64.29	0.459	0.498
≥20	31	30.69	21	28.77	10	35.71
Tumor invasion
T1 and T2	35	34.65	20	27.40	15	53.57	6.123	0.013
T3 and T4	66	65.35	53	72.60	13	46.43
Lymph node metastasis
Negative	47	46.53	29	39.73	18	64.29	4.906	0.027
Positive	54	53.47	44	60.27	10	35.71
Clinic stages (TNM)
I and II	45	44.55	28	38.36	17	60.71	4.095	0.043
III and IV	56	55.45	45	61.64	11	39.29